Observational study identifies rare MET gene variants linked to fatty liver disease — Evidence Review

Scientists at Mayo Clinic have identified a rare inherited mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease (MASLD), challenging the prevailing view that such liver disorders result mainly from a combination of genetic risk and environmental factors. Related studies broadly support the significant role of rare genetic variants in fatty liver disease susceptibility and progression, aligning with these new findings from Hepatology and further highlighting the complexity of genetic influences in liver disease.

• Several large-scale studies demonstrate that rare genetic variants, including those affecting genes involved in lipid metabolism and autophagy (such as PEMT, ATG7, and CIDEB), can substantially influence the risk and severity of fatty liver diseases, supporting the notion that single-gene mutations may have strong effects in select cases 1 8 9.
• While the majority of research has focused on common polygenic risk, recent evidence highlights the contribution of rare, sometimes family-specific, variants that can both predispose to and protect against liver disease, expanding the spectrum of genetic involvement 4 6 7 8.
• The new study’s identification of MET gene variants as a causative factor in MASLD complements previous findings by demonstrating that rare germline mutations outside the most commonly studied genes (e.g., PNPLA3, HSD17B13) may be under-recognized contributors to disease, especially in the absence of traditional metabolic risk factors 4 7 9.

Study Overview and Key Findings

Metabolic dysfunction-associated steatotic liver disease (formerly known as nonalcoholic fatty liver disease) affects about one-third of adults worldwide and is a leading cause of advanced liver complications. The recent Mayo Clinic study is notable for identifying a single rare variant in the MET gene that appears to directly cause MASLD in a subset of patients, moving beyond the general understanding that the disease is mainly multifactorial. The discovery emerged from detailed genomic analysis of a family with MASLD unexplained by typical risk factors and was further validated using data from a large-scale sequencing initiative. This work illustrates the potential of precision genomic medicine to uncover hidden genetic drivers of common diseases and to guide more personalized diagnostic and therapeutic approaches.

Property	Value
Organization	Mayo Clinic, Medical College of Wisconsin
Journal Name	Hepatology
Authors	Filippo Pinto e Vairo, Raul Urrutia, Konstantinos Lazaridis
Population	Adults with metabolic dysfunction-associated steatotic liver disease
Sample Size	n=100,000 participants in Tapestry study, n=4,000 adults with liver disease
Methods	Observational Study
Outcome	Identification of rare genetic variants related to liver disease
Results	1% of adults with liver disease carried rare MET gene variants.

Literature Review: Related Studies

To assess how these new findings fit into the broader research landscape, we searched the Consensus database, which includes over 200 million research papers. The following queries were used to identify relevant studies:

1. MET gene mutation fatty liver disease
2. rare genetic variants liver disease
3. prevalence gene mutations hepatic disorders

Literature Review Table

Topic	Key Findings
How do rare genetic variants influence the risk and severity of fatty liver disease?	- Rare variants in genes such as PEMT, ATG7, and CIDEB are associated with increased or decreased risk of fatty liver disease, with some variants directly predisposing to severe disease and others offering protection 1 8 9. - Inherited rare pathogenic variants can increase susceptibility to hepatocellular carcinoma in NAFLD patients 7.
What mechanisms link rare gene mutations to liver disease progression and outcomes?	- Loss-of-function mutations can disrupt lipid metabolism, autophagy, or mitochondrial function, leading to fat accumulation, inflammation, and fibrosis 1 3 9. - Some variants in metabolism-related genes (e.g., HSD17B13, CIDEB) are protective and associated with lower liver enzyme levels and reduced disease severity 6 8.
Can large-scale genomic studies help identify new therapeutic targets for liver disease?	- Genome-wide and exome sequencing studies have uncovered new risk loci and protective variants, highlighting potential targets such as GPAM, CIDEB, and HSD17B13 for intervention 6 8 10. - Polygenic and rare variant analyses improve prediction and stratification of liver disease progression and may inform precision therapies 4 10.

---

How do rare genetic variants influence the risk and severity of fatty liver disease?

Recent studies demonstrate that rare genetic variants can have a strong impact on the risk, severity, and clinical outcomes of fatty liver disease, both by predisposing individuals to advanced forms and by conferring protection. The new Mayo Clinic study’s identification of MET gene variants as high-impact contributors is consistent with previous findings in genes such as PEMT, ATG7, and CIDEB, underscoring the importance of rare variants beyond the traditionally studied common variants.

• Rare loss-of-function variants in PEMT increase susceptibility to NAFLD by disrupting phosphatidylcholine synthesis, mirroring the impact of MET variants on lipid metabolism 1.
• ATG7 rare variants impair autophagy and promote progression from steatosis to more severe liver pathology, including cirrhosis and cancer 9.
• Inherited rare pathogenic variants are overrepresented among NAFLD patients who develop hepatocellular carcinoma, emphasizing their clinical relevance 7.
• The prevalence and impact of rare variants are increasingly recognized as contributing to both familial and apparently sporadic cases of severe liver disease 7 9.

What mechanisms link rare gene mutations to liver disease progression and outcomes?

Mechanistic studies indicate that rare gene mutations can alter fundamental cellular processes—such as lipid handling, autophagy, and mitochondrial function—thereby driving or modulating the pathogenesis of fatty liver disease. The new findings on MET gene disruption fit within this paradigm, as the mutation impairs fat metabolism and liver repair, leading to disease progression.

• Loss-of-function mutations in genes like PEMT and ATG7 disrupt lipid processing or autophagy, resulting in fat accumulation, hepatocellular injury, and fibrosis 1 9.
• Some rare mutations, such as those in HSD17B13 and CIDEB, are protective, reducing liver enzyme levels and the risk of progression from steatosis to more severe disease forms 6 8.
• Alterations in mitochondrial structure and function have also been implicated in disease severity, though not all mutations affecting these pathways result in classic NAFLD phenotypes 3 5.
• These mechanisms highlight the diversity of genetic influences, with both risk-increasing and protective effects depending on the gene and variant involved 6 8 9.

Can large-scale genomic studies help identify new therapeutic targets for liver disease?

Large-scale sequencing initiatives have accelerated the discovery of novel genetic variants associated with liver disease risk and progression, leading to the identification of both risk and protective alleles that may serve as therapeutic targets. The Tapestry study’s approach in the new Mayo Clinic research exemplifies this trend, with implications for future precision medicine strategies.

• Genome-wide association and exome sequencing studies have uncovered new risk loci (e.g., GPAM, PNPLA3) and protective variants (e.g., HSD17B13, CIDEB), suggesting possible pathways for intervention 4 6 8 10.
• Polygenic and rare variant analyses can improve the prediction of disease progression and enable the stratification of patients for targeted therapies 4 7 10.
• The integration of genomic data with clinical information facilitates the identification of high-risk individuals and may inform the development of individualized treatment approaches 4 10.
• As illustrated by the MET variant discovery, large genomic datasets can reveal rare but impactful mutations that may otherwise go undetected, broadening the genetic landscape of liver disease 4 10.

Future Research Questions

Although this study highlights the role of rare MET gene variants in MASLD, several important questions remain. Further research is needed to clarify the functional impact of these and other rare variants, assess their prevalence across diverse populations, and explore the therapeutic potential of targeting implicated pathways. Addressing these questions could enhance understanding and management of fatty liver diseases.

Research Question	Relevance
What is the global prevalence and population distribution of rare MET gene variants in MASLD?	Understanding variant prevalence in different populations is essential for assessing clinical impact, guiding screening efforts, and informing genetic counseling 4 7 9.
How do rare MET gene mutations alter liver cell biology and disease progression?	Functional studies are needed to uncover the precise molecular and cellular mechanisms by which MET variants drive fat accumulation and liver injury, informing targeted interventions 1 3 9.
Can screening for rare genetic variants improve early diagnosis and risk stratification in MASLD?	Integrating rare variant analysis into clinical practice may help identify high-risk individuals who would otherwise go undetected, potentially enabling earlier intervention 4 7 10.
What therapeutic approaches could target pathways affected by rare MET gene variants in liver disease?	Elucidating the druggability of pathways impacted by MET or similar mutations may lead to new treatments for patients with genetically driven MASLD 4 6 8 10.
How do rare genetic variants interact with common risk alleles and environmental factors in MASLD progression?	Investigating gene-gene and gene-environment interactions will clarify the overall risk architecture and may uncover modifiable factors that influence disease outcomes 2 4 10.